149 Extent of Female Partner Sexual Function Improvement in Female Partners of Men With Peyronie's Disease Who Received Collagenase Clostridium Histolyticum

Abstract

To examine the impact of erectile dysfunction severity in men with Peyronie's disease (PD) on improvement of female partner satisfaction after collagenase clostridium histolyticum (CCH) treatment. Men with PD (penile curvature ≥30° and ≤90°) who previously received placebo during the IMPRESS I or II trials and their female partners, who were willing to participate, were included in a separate subsequent open-label, phase 3 study. Men received up to 4 treatment cycles; cycles were separated by 6 weeks. Each treatment cycle consisted of 2 injections of CCH 0.58 mg separated by 24 to 72 hours. The second injection was followed by 6 weeks of daily penile plaque modeling. Men completed the International Index of Erectile Function (IIEF) at baseline and week 36. The IIEF is a 15-item questionnaire that assesses 5 domains (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction) of male sexual function. Female sexual function was assessed at baseline and week 36 using the Female Sexual Function Index (FSFI), a 19-item questionnaire that measures desire or arousal, lubrication, orgasm, satisfaction, and pain. The relationship between baseline IIEF male erectile dysfunction and improvement of female sexual function after CCH therapy in males was examined using regression analysis (Pearson correlation coefficient [r]).